EUR 106.34 For Business Accounts Only

SciClone Pharmaceuticals Inc - Strategic SWOT Analysis Review

SciClone Pharmaceuticals Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – GlobalData’s summarization of the company’s business strategy.
- SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.

Highlights

SciClone Pharmaceuticals Inc (SciClone), a subsidiary of Silver Biotech Investment Ltd, develops and commercializes products for the treatment of cancer, cardiovascular disorders and infectious diseases. The company’s lead product, Zadaxin (thymalfasin) is an immunostimulatory agent indicated for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), sepsis, certain cancers, and as an immune system enhancer. SciClone also markets other pharmaceutical products in China including DC Bead, a product for the embolization of malignant hypervascularized tumors. It also has several drug candidates in various clinical development states intended for the treatment of cancer and cardiovascular diseases. The company has presence in Beijing and Shanghai in China; Hong Kong and Vietnam. SciClone is headquartered in Foster City, California, the US.

SciClone Pharmaceuticals Inc Key Recent Developments

Aug 09,2017: SciClone Reports Second Quarter 2017 Financial Results
May 10,2017: SciClone Reports First Quarter 2017 Financial Results
Mar 06,2017: SciClone Reports 2016 Financial Results And 2017 Outlook

Reasons to Buy

- Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
- Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
- Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.